Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Bristol-Myers Squibb
Posted inOncology, Regulatory
Opdivo and Keytruda: First-line Immunotherapy for Gastric Cancer and Esophageal Cancer
Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.
Posted inClinical Trials, In the Pipeline, Oncology, Regulatory
Small Cell Lung Cancer: Let Immunotherapy Help!
A deadly disease and modern pharmacological attempts to treat it.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis
Siponimod released by Novartis is an improved version of Gilenya.